Crawford Investment Counsel Inc. Sells 1,520 Shares of Bristol-Myers Squibb Company (BMY)
Crawford Investment Counsel Inc. decreased its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 7.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,961 shares of the biopharmaceutical company’s stock after selling 1,520 shares during the quarter. Crawford Investment Counsel Inc.’s holdings in Bristol-Myers Squibb were worth $1,001,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of the business. State Street Corp increased its holdings in Bristol-Myers Squibb by 1.8% during the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after purchasing an additional 1,223,457 shares during the period. Jennison Associates LLC boosted its position in shares of Bristol-Myers Squibb by 5.4% during the 2nd quarter. Jennison Associates LLC now owns 23,118,789 shares of the biopharmaceutical company’s stock worth $1,288,179,000 after acquiring an additional 1,184,652 shares in the last quarter. Ameriprise Financial Inc. boosted its position in shares of Bristol-Myers Squibb by 18.7% during the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after acquiring an additional 2,451,390 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Bristol-Myers Squibb by 2.7% during the 2nd quarter. Legal & General Group Plc now owns 8,431,348 shares of the biopharmaceutical company’s stock worth $469,802,000 after acquiring an additional 217,920 shares in the last quarter. Finally, Swiss National Bank boosted its position in shares of Bristol-Myers Squibb by 27.2% during the 1st quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after acquiring an additional 1,267,900 shares in the last quarter. Institutional investors own 69.51% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Crawford Investment Counsel Inc. Sells 1,520 Shares of Bristol-Myers Squibb Company (BMY)” was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://theolympiareport.com/2017/11/17/crawford-investment-counsel-inc-sells-1520-shares-of-bristol-myers-squibb-company-bmy.html.
Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at $61.87 on Friday. Bristol-Myers Squibb Company has a 1 year low of $46.01 and a 1 year high of $66.10. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. The firm has a market capitalization of $99,953.27, a P/E ratio of 20.63, a price-to-earnings-growth ratio of 2.41 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same period in the previous year, the business posted $0.77 earnings per share. The firm’s revenue was up 6.7% compared to the same quarter last year. equities analysts predict that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.52%. Bristol-Myers Squibb’s payout ratio is 61.42%.
Several research analysts have recently issued reports on BMY shares. UBS AG reaffirmed a “buy” rating and set a $72.00 price objective (up from $62.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 6th. Vetr raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 price objective for the company in a research report on Monday, October 9th. Zacks Investment Research cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. BMO Capital Markets reaffirmed a “sell” rating and set a $49.00 price objective on shares of Bristol-Myers Squibb in a research report on Monday, September 4th. Finally, Citigroup Inc. upped their price objective on Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, October 18th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $64.93.
In other news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the transaction, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.23% of the stock is currently owned by company insiders.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.